Wexler RR - Search Results

1

Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues.

Qiao JX, Cheng X, Smallheer JM, Galemmo RA, Drummond S, Pinto DJ, Cheney DL, He K, Wong PC, Luettgen JM, Knabb RM, Wexler RR, Lam PY. Qiao JX, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1432-7. doi: 10.1016/j.bmcl.2006.11.071. Epub 2006 Dec 1. Bioorg Med Chem Lett. 2007. PMID: 17174550

2

The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist.

Duncia JV, Carini DJ, Chiu AT, Johnson AL, Price WA, Wong PC, Wexler RR, Timmermans PB. Duncia JV, et al. Among authors: wexler rr. Med Res Rev. 1992 Mar;12(2):149-91. doi: 10.1002/med.2610120203. Med Res Rev. 1992. PMID: 1619965 Review. No abstract available.

3

The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists.

Timmermans PB, Carini DJ, Chiu AT, Duncia JV, Price WA Jr, Wells GJ, Wong PC, Johnson AL, Wexler RR. Timmermans PB, et al. Among authors: wexler rr. Am J Hypertens. 1991 Apr;4(4 Pt 2):275S-281S. doi: 10.1093/ajh/4.4.275s. Am J Hypertens. 1991. PMID: 1854452 Review.

4

Balanced AT1/AT2 receptor antagonists. 4. XR510 and related 5-(3-amidopropanoyl)imidazoles possessing equal affinity for the AT1 and AT2 receptors.

Quan ML, Chiu AT, Ellis CD, Wong PC, Wexler RR, Timmermans PB. Quan ML, et al. Among authors: wexler rr. J Med Chem. 1995 Jul 21;38(15):2938-45. doi: 10.1021/jm00015a016. J Med Chem. 1995. PMID: 7636854

5

A novel series of selective, non-peptide inhibitors of angiotensin II binding to the AT2 site.

VanAtten MK, Ensinger CL, Chiu AT, McCall DE, Nguyen TT, Wexler RR, Timmermans PB. VanAtten MK, et al. Among authors: wexler rr. J Med Chem. 1993 Dec 10;36(25):3985-92. doi: 10.1021/jm00077a001. J Med Chem. 1993. PMID: 8258820

6

Discovery of losartan, the first angiotensin II receptor antagonist.

Timmermans PB, Duncia JV, Carini DJ, Chiu AT, Wong PC, Wexler RR, Smith RD. Timmermans PB, et al. Among authors: wexler rr. J Hum Hypertens. 1995 Nov;9 Suppl 5:S3-18. J Hum Hypertens. 1995. PMID: 8583479 Review.

7

Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists.

Wityak J, Sielecki TM, Pinto DJ, Emmett G, Sze JY, Liu J, Tobin AE, Wang S, Jiang B, Ma P, Mousa SA, Wexler RR, Olson RE. Wityak J, et al. Among authors: wexler rr. J Med Chem. 1997 Jan 3;40(1):50-60. doi: 10.1021/jm960626t. J Med Chem. 1997. PMID: 9016328

8

Pyrazoles, 1,2,4-triazoles, and tetrazoles as surrogates for cis-amide bonds in boronate ester thrombin inhibitors.

Duncia JV, Santella JB 3rd, Higley CA, VanAtten MK, Weber PC, Alexander RS, Kettner CA, Pruitt JR, Liauw AY, Quan ML, Knabb RM, Wexler RR. Duncia JV, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 1998 Apr 7;8(7):775-80. doi: 10.1016/s0960-894x(98)00104-8. Bioorg Med Chem Lett. 1998. PMID: 9871540

9

Rational design of boropeptide thrombin inhibitors: beta, beta-dialkyl-phenethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor I and an improved safety profile.

Fevig JM, Buriak J Jr, Cacciola J, Alexander RS, Kettner CA, Knabb RM, Pruitt JR, Weber PC, Wexler RR. Fevig JM, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 1998 Feb 3;8(3):301-6. doi: 10.1016/s0960-894x(98)00013-4. Bioorg Med Chem Lett. 1998. PMID: 9871674

10

The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies.

Galemmo RA Jr, Maduskuie TP, Dominguez C, Rossi KA, Knabb RM, Wexler RR, Stouten PF. Galemmo RA Jr, et al. Among authors: wexler rr. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2705-10. doi: 10.1016/s0960-894x(98)00471-5. Bioorg Med Chem Lett. 1998. PMID: 9873607

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

195 results

Search Page